How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 901–1,000 of 1,024
Connectosomes for Direct Molecular Delivery to the Cellular Cytoplasm
Gadok, A. K., Busch, D. J., Ferrati, S., Li, B., Smyth, H. D. C., & Stachowiak, J. C. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05191 · Cited by 49
A kinetic study of bitter taste receptor sensing using immobilized porcine taste bud tissues
Wei, L., Qiao, L., Pang, G., & Xie, J. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.01.064 · Cited by 47
Carbohydrate-Based Therapeutics
Mishra, S., Upadhaya, K., Mishra, K. B., Shukla, A. K., Tripathi, R. P., & Tiwari, V. K. (2016) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63601-0.00010-7 · Cited by 54
Carbene Footprinting Reveals Binding Interfaces of a Multimeric Membrane‐Spanning Protein
Manzi, L., Barrow, A. S., Hopper, J. T. S., Kaminska, R., Kleanthous, C., Robinson, C. V., Moses, J. E., & Oldham, N. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201708254 · Cited by 51
Introducing SEC–SANS for studies of complex self-organized biological systems
Johansen, N. T., Pedersen, M. C., Porcar, L., Martel, A., & Arleth, L. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318007180 · Cited by 48
Heterogeneous Dielectric Implicit Membrane Model for the Calculation of MMPBSA Binding Free Energies
Greene, D., Qi, R., Nguyen, R., Qiu, T., & Luo, R. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00363 · Cited by 48
Small molecule chemical probes of microRNA function
Velagapudi, S. P., Vummidi, B. R., & Disney, M. D. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.10.024 · Cited by 46
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators
Ferrara, S. J., & Scanlan, T. S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00868 · Cited by 49
Application Progress of the Single Domain Antibody in Medicine
Tang, H., Gao, Y., & Han, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044176 · Cited by 54
Small-molecule modulators of 14-3-3 protein–protein interactions
Ottmann, C. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.028 · Cited by 56
Gul, S., & Hadian, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.954544 · Cited by 54
“However, despite this challenging aspect from a drug discovery perspective, PPIs are implicated in a multitude of key biological processes in normal and disease states thus offering an attractive avenue for therapeutic intervention [4].”
BackgroundBiasing GPCR Signaling from Inside
Shukla, A. K. (2014) · Science Signaling · doi:10.1126/scisignal.2005021 · Cited by 48
“The concept of biased signaling has primarily been developed and discussed in the context of ligands that bind to the extracellular regions of GPCRs.”
BackgroundInfluentialYang, J., Jang, R., Zhang, Y., & Shen, H. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt440 · Cited by 48
“Tested on 60 non-redundant polytopic proteins using a strict leave-one-out cross-validation protocol, MemBrain achieves an average accuracy of 62%, which is 12.5% higher than the current best method from the literature.”
MethodInfluentialAccessible Mannitol‐Based Amphiphiles (MNAs) for Membrane Protein Solubilisation and Stabilisation
Hussain, H., Du, Y., Scull, N. J., Mortensen, J. S., Tarrasch, J. T., Bae, H. E., Loland, C. J., Byrne, B., Kobilka, B. K., & Chae, P. S. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600533 · Cited by 46
Electron Cryo‐microscopy as a Tool for Structure‐Based Drug Development
Merino, F., & Raunser, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201608432 · Cited by 50
Pollak, J., Rai, K. G., Funk, C. C., Arora, S., Lee, E., Zhu, J., Price, N. D., Paddison, P. J., Ramirez, J., & Rostomily, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172884 · Cited by 53
“Ion channel and transporter targeting drugs are currently used to treat a variety of clinical conditions and represented over 13% of FDA-approved drugs in 2006—the second largest class of existing drugs [39].”
BackgroundPluskal, T., & Weng, J. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 50
Folding and stabilizing membrane proteins in amphipol A8-35
Bon, C. L., Marconnet, A., Masscheleyn, S., Popot, J., & Zoonens, M. A. (2018) · Methods · doi:10.1016/j.ymeth.2018.04.012 · Cited by 46
The lipid environment of Escherichia coli Aquaporin Z
Schmidt, V., Sidore, M., Bechara, C., Duneau, J., & Sturgis, J. N. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.10.017 · Cited by 54
“Because of this important role, they are the targets of more than 50% of drugs currently on the market [1].”
BackgroundBiochemical studies of membrane fusion at the single-particle level
Tian, Z., Gong, J., Crowe, M., Lei, M., Li, D., Ji, B., & Diao, J. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.01.001 · Cited by 49
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease
Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.02.004 · Cited by 46
Yakubu, R., Nieves, E., & Weiss, L. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_10 · Cited by 46
Collision Induced Unfolding Classifies Ligands Bound to the Integral Membrane Translocator Protein
Fantin, S. M., Parson, K. F., Niu, S., Liu, J., Polasky, D. A., Dixit, S. M., Ferguson-Miller, S. M., & Ruotolo, B. T. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03208 · Cited by 53
Probing Orientations and Conformations of Peptides and Proteins at Buried Interfaces
Guo, W. X., Lu, T., Gandhi, Z. A., & Chen, Z. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c02956 · Cited by 50
Promiscuous drugs as therapeutics for chemokine receptors
Horuk, R. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000921 · Cited by 51
Karhemo, P., Ravela, S., Laakso, M., Ritamo, I., Tatti, O., Mäkinen, S., Goodison, S., Stenman, U., Hölttä, E., Hautaniemi, S., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.07.009 · Cited by 55
“[7] Overington JP, Al-Lazikani B, Hopkins AL.”
BackgroundProdrugs forming multifunctional supramolecular hydrogels for dual cancer drug delivery
Ha, W., Yu, J., Song, X., Zhang, Z., Liu, Y., & Shi, Y. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20956c · Cited by 45
Targeting tight junction proteins-significance for drug development
Kondoh, M., Yoshida, T., Kakutani, H., & Yagi, K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.005 · Cited by 49
Idealizing Ion Channel Recordings by a Jump Segmentation Multiresolution Filter
Hotz, T., Schütte, O. M., Sieling, H., Polupanow, T., Diederichsen, U., Steinem, C., & Munk, A. (2013) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2013.2284063 · Cited by 45
“Being involved in many human diseases such as epilepsy, cardiac arrythmias, and others, they are major targets of pharmaceutical drugs [2], [3].”
BackgroundHounsou, C., Margathe, J., Oueslati, N., Belhocine, A., Dupuis, E., Thomas, C., Mann, A., Ilien, B., Rognan, D., Trinquet, E., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb5007568 · Cited by 49
Hohenhaus, D. M., Schaale, K., Cao, K. L., Seow, V., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.07.001 · Cited by 55
Systems genetics for drug target discovery
Penrod, N. M., Sallari, R. C., & Moore, J. H. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.002 · Cited by 51
“Imatinib has been FDA-approved for use in BCR-ABL -positive CML patients since 2001.”
BackgroundFilizola, M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.05.004 · Cited by 48
“2008), are the primary targets for about 30% of prescription drugs (Overington et al. 2006), and are likely to be potential targets for new therapeutic drugs (Xiao et al.”
BackgroundTargeting transcription factors for therapeutic benefit
Brennan, P., Donev, R., & Hewamana, S. (2008) · Molecular BioSystems · doi:10.1039/b801920g · Cited by 53
Shiroishi, M., Tsujimoto, H., Makyio, H., Asada, H., Yurugi-Kobayashi, T., Shimamura, T., Murata, T., Nomura, N., Haga, T., Iwata, S., et al. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-78 · Cited by 45
“GPCRs are major therapeutic drug targets and represent ~ 30% of the market share of all prescription drugs [1].”
BackgroundA class of rigid linker-bearing glucosides for membrane protein structural study
Sadaf, A., Mortensen, J. S., Capaldi, S., Tikhonova, E. B., Hariharan, P., Ribeiro, O., Loland, C. J., Guan, L., Byrne, B., & Chae, P. S. (2015) · Chemical Science · doi:10.1039/c5sc02900g · Cited by 48
AUC and Small-Angle Scattering for Membrane Proteins
Roy, A. L., Wang, K., Schaack, B., Schuck, P., Breyton, C., & Ebel, C. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.06.010 · Cited by 45
Kalxdorf, M., Gade, S., Eberl, H. C., & Bantscheff, M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063859 · Cited by 47
“( 10%) are the most frequently targeted protein classes (7, 8).”
BackgroundFluorescence strategies for mapping cell membrane dynamics and structures
Sankaran, J., & Wohland, T. (2020) · APL Bioengineering · doi:10.1063/1.5143945 · Cited by 48
Charoenkwan, P., Schaduangrat, N., Lió, P., Moni, M. A., Shoombuatong, W., & Manavalan, B. (2022) · iScience · doi:10.1016/j.isci.2022.104883 · Cited by 45
“As such, the druggability of a protein is crucial for the progression of a drug discovery project, wherein the accurate identification of drug targets is necessary (Overington et al., 2006).”
BackgroundStructural genomics and drug discovery: all in the family
Weigelt, J., McBroom, L. D. B., Schapira, M., Zhao, Y., & Arrowmsmith, C. H. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.045 · Cited by 50
DBP-DeepCNN: Prediction of DNA-binding proteins using wavelet-based denoising and deep learning
Ali, F., R, H. K. G., Patil, S., Ahmed, A., Banjar, A., & Daud, A. Y. (2022) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2022.104639 · Cited by 46
Du, R., Wang, C., Zhu, L., & Yang, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102236 · Cited by 46
“Only 3000 of the roughly 20,000 proteins encoded by the human genome are druggable, and only 700 have corresponding drugs in development [2,3].”
BackgroundHTS assays for developing the molecular pharmacology of ion channels
McManus, O. B. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.01.004 · Cited by 47
“Approximately 13% of FDA approved drugs target ion channels, a value that is similar to the number targeting nuclear receptors, and second only to G protein coupled receptors (GPCRs) as a target class [1].”
BackgroundLeung, E. Y., Hung, J. M., Barker, D. L. A., & Reynisson, J. (2013) · MedChemComm · doi:10.1039/c3md00290j · Cited by 46
Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators
Valant, C., Aurelio, L., Urmaliya, V., White, P. J., Scammells, P. J., Sexton, P. M., & Christopoulos, A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064568 · Cited by 44
“G protein-coupled receptors (GPCRs) are the largest family of cell surface proteins (Lagerström and Schiöth, 2008) and remain pre-eminent targets for novel drug discovery (Overington et al., 2006).”
BackgroundG Protein-Coupled Receptors in Myelinating Glia
Mogha, A., D’Rozario, M., & Monk, K. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.002 · Cited by 48
“GPCRs have emerged as major pharmacological drug targets due to their key roles in a variety of physiological functions in disease and health, and GPCR modulators represent at least one-third of all clinically marketed drugs [4].”
BackgroundFast iodide-SAD phasing for high-throughput membrane protein structure determination
Melnikov, I., Polovinkin, V., Kovalev, K., Gushchin, I., Shevtsov, M. B., Shevchenko, V., Mishin, A., Alekseev, A. A., Rodríguez‐Valera, F., Borshchevskiy, V. I., et al. (2017) · Science Advances · doi:10.1126/sciadv.1602952 · Cited by 50
“However, although they are also extremely important drug targets [up to 60%of all existing drug targets areMPs (2)], they still remain poorly structurally characterized compared to soluble proteins, mainly because their production and crystallization are two major bottlenecks of structural biology.”
BackgroundStructural and Functional View of Polypharmacology
Moya‐García, A. A., Adeyelu, T. T., Krüger, F. A., Dawson, N. L., Lees, J., Overington, J. P., Orengo, C. A., & Ranea, J. A. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10012-x · Cited by 49
Self-citationJi, B., You, Z.-H., Jiang, H.-J., Guo, Z.-H., & Zheng, K. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02490-x · Cited by 44
The promise of graphene-based transistors for democratizing multiomics studies
Lu, H., Kane, A. A., Parkinson, J., Gao, Y., Hajian, R., Heltzen, M., Goldsmith, B. R., & Aran, K. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113605 · Cited by 45
Lu, Z., van Niekerk, D. C., Savva, A., Kallitsis, K., Thiburce, Q., Salleo, A., Pappa, A., & Owens, R. M. (2022) · Journal of Materials Chemistry C · doi:10.1039/d2tc00826b · Cited by 44
Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines
Hillger, J. M., Schoop, J., Boomsma, D. I., Slagboom, P. E., IJzerman, A. P., & Heitman, L. H. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.06.031 · Cited by 49
“The majority of therapeutic targets to date are formed by a class of membrane proteins, the G protein-coupled receptors (GPCRs) (Overington et al., 2006).”
BackgroundGPCR Signaling: Understanding the Pathway to Successful Drug Discovery
Williams, C., & Hill, S. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-317-6_3 · Cited by 44
Baâti, T., Horcajada, P., Gref, R., Couvreur, P., & Serre, C. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.07.011 · Cited by 45
Inhibition of Cytochromes P450: Existing and New Promising Therapeutic Targets
Schuster, I., & Bernhardt, R. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701498455 · Cited by 48
“Within the 10 most commonly drugged families, cytochromes P450 hold the tenth position, sharing 1.9% of all FDA-approved drugs (Overington et al., 2006).”
BackgroundInfluentialCameron, R. B., Peterson, Y. K., Beeson, C., & Schnellmann, R. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-11030-5 · Cited by 46
Taechalertpaisarn, J., Ono, S., Okada, O., Johnstone, T. C., & Lokey, R. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00010 · Cited by 43
Emergence of mass spectrometry detergents for membrane proteomics
Behnke, J., & Urner, L. H. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04584-z · Cited by 54
“Even though the membrane-bound proteome marks only 30% of the genetically encoded proteome, it accounts for 60% of current drug targets [4, 5].”
BackgroundRecent advances in membrane mimetics for membrane protein research
Young, J. W. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230164 · Cited by 54
Natural Products Drug Discovery
Appendino, G., Fontana, G., & Pollastro, F. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00064-2 · Cited by 56
Tan, F., Yang, R., Xu, X., Chen, X., Wang, Y., Ma, H., Liu, X., Wu, X., Chen, Y., Liu, L., et al. (2014) · Molecular BioSystems · doi:10.1039/c3mb70554d · Cited by 50
Satyanarayanajois, S. D., & Hill, R. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.135 · Cited by 49
Ding, X., Zhao, X., & Watts, A. G. (2013) · Biochemical Journal · doi:10.1042/bj20121644 · Cited by 50
Folding and function in α/β-peptides: targets and therapeutic applications
Werner, H. M., & Horne, W. S. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.06.013 · Cited by 50
Wang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W., & Wang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw018 · Cited by 49
Khan, M. S., Dosoky, N. S., Berdiev, B. K., & Williams, J. D. (2016) · European Biophysics Journal · doi:10.1007/s00249-016-1156-8 · Cited by 43
“Ion-channel proteins are one of the major targets for drug design (Overington et al. 2006), and black lipid membrane (BLM) has been chosen as a biomimetic model for development of a hybrid electrochemical biosensor to investigate protein channel events (Khan et al.”
BackgroundDrug‐Mediated Regulation of Glycosaminoglycan Biosynthesis
Ghiselli, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21429 · Cited by 46
Wang, Q., Feng, Y., Huang, J., Wang, T., & Cheng, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176486 · Cited by 42
Teng, W., Huang, P.-H., Wang, H., Tseng, C.-H., & Yen, F. (2021) · Antioxidants · doi:10.3390/antiox10101552 · Cited by 51
Giardina, S. F., Werner, D. S., Pingle, M., Feinberg, P. B., Foreman, K. W., Bergstrom, D. E., Arnold, L. D., & Barany, F. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01689 · Cited by 46
Expression of Olfactory Signaling Genes in the Eye
Pronin, A. N., Levay, K., Velmeshev, D., Faghihi, M. A., Shestopalov, V. I., & Slepak, V. Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096435 · Cited by 43
“These features benefit pharmacologic intervention, and targeting GPCRs in the past decades brought about revolutionary success in many areas, for example, neuropharmacology and treatment of cardiovascular diseases [5,6].”
BackgroundStructural genomics target selection for the New York consortium on membrane protein structure
Punta, M., Love, J. D., Handelman, S. K., Hunt, J. F., Shapiro, L. S., Hendrickson, W. A., & Rost, B. (2009) · Journal of Structural and Functional Genomics · doi:10.1007/s10969-009-9071-1 · Cited by 44
“At NYCOMPS, we have so far focused only on a IMPs, because of their abundance in genomes and high biological and medical relevance [6, 14]. a IMPs are among the most difficult proteins for structure determination studies [15–17].”
BackgroundPredict potential drug targets from the ion channel proteins based on SVM
Huang, C. L., Zhang, R., Chen, Z., Jiang, Y., Shang, Z., Sun, P. G., Zhang, X., & Li, X. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.002 · Cited by 47
Targeting Protein-Protein Interactions for Drug Discovery
Fry, D. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2425-7_6 · Cited by 45
Desenvolvimento de Medicamentos no Brasil: Desafios
Calixto, J. Β., & Siqueira, J. M. (2008) · Gazeta Médica da Bahia · Cited by 85
Which three-dimensional characteristics make efficient inhibitors of protein–protein interactions?
Kuenemann, M. A., Bourbon, L. M. L., Labbé, C. M., Villoutreix, B. O., & Sperandio, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500487q · Cited by 42
Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk
Yu, L., Su, R., Wang, B., Zhang, L., Zou, Y., Zhang, J., & Gao, L. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2550453 · Cited by 42
Tang, K., Tang, Z., Niu, M., Kuang, Z., Xue, W., Wang, X., Liu, X., Yu, Y., Jeong, S. D., Ma, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58746-x · Cited by 46
“Membrane proteins account for more than 60% of the currently available drug targets 9 .”
Chemogenomic Discovery of Allosteric Antagonists at the GPRC6A Receptor
Gloriam, D. E. I., Wellendorph, P., Johansen, L. D., Thomsen, A. R. B., Phonekeo, K., Pedersen, D. S., & Bräuner‐Osborne, H. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.09.012 · Cited by 43
“A large proportion of current drugs (27%–45%) exert their effect via GPCRs, including well-known examples such as morphine and propranolol, but the majority of the receptors in this protein superfamily are as yet untapped for potential therapies (Drews, 2000; Hopkins and Groom, 2002; Overington et al., 2006).”
BackgroundInfluentialHistamine regulation of innate and adaptive immunity
Ferstl, R., Akdiş, C. A., & O’Mahony, L. (2011) · Frontiers in bioscience · doi:10.2741/3914 · Cited by 47
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Structure and function of G protein-coupled receptors using NMR spectroscopy
Goncalves, J. A., Ahuja, S., Erfani, S., Eilers, M., & Smith, S. O. (2010) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2010.04.004 · Cited by 47
Bánky, D., Iván, G., & Grolmusz, V. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054204 · Cited by 44
“The FDA approved drugs target presently only 324 human and pathogen proteins [10] from at least tens of thousands of possible proteins, therefore any well-founded method that may help to identify new ones has a substantial value.”
BackgroundWrzal, P. K., Devost, D., Pétrin, D., Goupil, E., Iorio‐Morin, C., Laporte, S. A., Zingg, H. H., & Hébert, T. E. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.09.020 · Cited by 42
Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers
Roshan‐Moniri, M., Hsing, M., Butler, M. S., Cherkasov, A. R., & Rennie, P. S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.005 · Cited by 49
“Thus, the unique presence of the ligand binding domain in NRs has made them very attractive drug targets, and NRs are among the top four families of drug targets and account for approximately 13% of all Food and Drug Administration (FDA)-approved drugs [5].”
BackgroundAnalysis of Commercial and Public Bioactivity Databases
Tiikkainen, P., & Franke, L. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2003126 · Cited by 52
Wang, W. C. H., Juan, A. H., Panebra, A., & Liggett, S. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101439108 · Cited by 44
“G receptors (GPCRs) regulate a large repertoire of physiological functions and their pathways are the most commonly targeted by current therapeutic agents (1).”
BackgroundWright, D. B., Tripathi, S., Sikarwar, A. S., Santosh, K., Perez‐Zoghbi, J. F., Ojo, O. O., Irechukwu, N., Ward, J. P. T., & Schaafsma, D. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.06.005 · Cited by 44
High-Resolution Structure of a Membrane Protein Transferred from Amphipol to a Lipidic Mesophase
Polovinkin, V., Gushchin, I., Sintsov, M. Y., Round, E. S., Balandin, T. G., Chervakov, P., Shevchenko, V., Utrobin, P., Popov, A. N., Borshchevskiy, V. I., et al. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9700-x · Cited by 49
“MPs represent roughly one-third of the proteins encoded in the human genome (Krogh et al. 2001), and about 60 % of all modern drugs have a MP as their target (Overington et al. 2006).”
BackgroundLangelaan, D. N., Reddy, T. J., Banks, A. W., Dellaire, G., Dupré, D. J., & Rainey, J. K. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.02.005 · Cited by 46
Co-assembled hybrids of proteins and carbon dots for intracellular protein delivery
Zhang, J., Zheng, M. J., & Xie, Z. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01622g · Cited by 43
Piccolo, N. D., Sarabipour, S., & Hristova, K. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755777 · Cited by 42
“The need for new basic knowledge is underscored by the fact that 60% of all Food and Drug Administration-approved therapeutics target membrane proteins (54).”
BackgroundZeng, W., Zhang, C., Cheng, H., Wu, Y., Liu, J., Chen, Z., Huang, J., Ericksen, R. E., Chen, L., Zhang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00233-5 · Cited by 44
Recent developments in solution nuclear magnetic resonance (NMR)-based molecular biology
Ziarek, J. J., Baptista, D., & Wagner, G. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1560-2 · Cited by 45
Hight, S. K., Mootz, A. A., Kollipara, R. K., McMillan, E. A., Yenerall, P. M., Yoichi, O., Li, L.-S., Avila, K., Peyton, M., Rodriguez‐Canales, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.04.005 · Cited by 67
Fiori, M. C., Zheng, W., Kamilar, E., Simiyu, G., Altenberg, G. A., & Liang, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-66852-7 · Cited by 42
New insight into lacrimal gland function: Role of the duct epithelium in tear secretion
Tóth‐Molnár, E., & Ding, C. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.07.002 · Cited by 44
“Lack of such kind of medications is especially notable in the light of the fact that at least 15% of our presently available human medications act on ion channels [106].”
BackgroundInfrared Scattering-Type Scanning Near-Field Optical Microscopy of Biomembranes in Water
Pfitzner, E., & Heberle, J. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c01769 · Cited by 42
Lipid Composition Alters Drug Action at the Nicotinic Acetylcholine Receptor
Baenziger, J. E., Ryan, S. E., Goodreid, M. M., Vuong, N. Q., Sturgeon, R. M., & daCosta, C. J. B. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.039008 · Cited by 42
“Given that over 50% of all drug targets are membrane proteins, understanding how drug action is influenced by the lipid bilayer is clearly of importance (Overington et al., 2006).”
Background
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.